Contineum Therapeutics heads into its May 7 Q1 2026 results with short sellers holding a meaningful position — but options traders telling a noticeably different story.
Short interest is a genuine factor here. At 13.5% of the free float, it has climbed roughly 16% over the past month, with a sharp step up around April 24 when shares jumped from ~2.83 million to ~3.12 million short in a single session. The ORTEX short score is 64.2, a level consistent with elevated bearish conviction. Yet the borrow market sends a conflicting signal: cost to borrow has ticked up 39% on the week to just 0.73%, and availability remains wide — shares are easy to borrow, meaning the short position is not under any mechanical squeeze pressure ahead of the print.
Options positioning, meanwhile, is more bullish than usual. The put/call ratio has dropped to 0.71, almost a full standard deviation below its 20-day average of 1.07. That's a distinct lean toward calls rather than downside protection — at odds with the elevated short interest and points to a divided market. The stock itself backs the optimistic camp for now: up 15% on the week and 7% over the past month, closing at $14.39 on Tuesday.
The analyst debate reflects the binary nature of the pipeline. Most of the Street is constructive — multiple Outperform ratings remain in place — with a consensus mean target around $22, roughly 54% above the current price. The bull case centres on a strong cash runway through 2027 (approximately $190 million) and Phase II data potential from PIPE-791 and PIPE-307 in MS, a large unmet-need indication with J&J as a development partner. Bears counter with the absence of any revenue, the risk of safety signals or regulatory setbacks, and heavy dependence on a single commercial partner. Morgan Stanley downgraded to Equal-Weight in January and cut its target to $14, essentially marking the floor of current trading — a note that still looms over the setup.
One institutional detail adds texture. Several specialist healthcare funds — including Janus Henderson, Baker Bros., and Balyasny — all initiated or sharply expanded positions in Q4 2025, with Janus entering fresh with 2.45 million shares. That kind of concentrated buy-in from name-brand biotech specialists raises the stakes of any clinical disappointment. On the insider side, the CSO and CEO have both made small routine sales under pre-planned plans across February–May, with roughly $548,000 in net selling over 90 days — modest in dollar terms and not a standout signal on its own.
Past earnings reactions have been uniformly negative: the stock fell on three of the last four prints, with a five-day average decline of roughly 5–8% following those events. Thursday's report is less a test of financials — there are none to speak of — and more a referendum on whether the PIPE-791 and PIPE-307 data readouts remain on track and whether J&J's partnership commitment shows any signs of evolution.
See the live data behind this article on ORTEX.
Open CTNM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
